Updated on 15 March 2013
"Initial capital for BravoBio came from the pocket of the founders," says Dr Wu Ke, pointing out that it takes six-to-eight years for a new vaccine to be launched. "Before that, the company must survive and sustainably develop," he adds. Therefore, apart from raising funds through partnerships, BravoBio is expecting that industrial joint ventures that focus on manufacturing and marketing vaccine-related diagnostic kits will turn profitable this year. "The international business is expected to bring revenue next year," informs Dr Wu Ke.
Shanghai BravoBio is organizing a joint venture with a publicly-listed company to develop and produce new vaccines on industrial scale. This will be the core entity of the company.
Moving ahead, Shanghai BravoBio plans to develop diagnostics and therapeutic macro-molecules, such as monoclonal antibodies (mAbs) and fusion proteins.
The corporate strategy is to integrate chain and resources to guide sustainable development. Quality and speed are two main factors considered by the team along with international partnership aimed for future growth.
On receiving BioSpectrum Asia Emerging Company of the Year Award, Dr Wu Ke says the company is delighted. "As a start-up with less than two years of history, we know BravoBio is still quite young and has long way to go. We are making a career by being valuable to human society and have a well-prepared strategy, plan, business model and partnership. We believe BravoBio will be an influential and respected biotech company from China in the coming seven-to-eight years that will be capable of supplying quality products to the global market and be beneficial to the people worldwide."